Variety of eligible individuals: CDEC mentioned the uncertainty in the number of patients with moderately severe to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some sufferers who will be classified as having mild or average disorder could have a extreme bleeding https://greatc468uvw1.tdlwiki.com/user